TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9678115
Drug: Monophasic oral
Normalized name: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic oral contraceptive containing 75 micrograms gestodene and 20 micrograms ethinylestradiol
Study: 21120497
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser therapy with a dosage of 1.2 J/per painful point
Study: 21120497
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser therapy with a dosage of 0.6 J/per painful point
Study: 20590735
Drug: glimepiride 8
Normalized name: glimepiride 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: glimepiride 8 mg
Study: 3631471
Drug: morphine 5
Normalized name: ethylmorphine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 5 mg
Study: 16119597
Drug: morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 1 mg with methylprednisolone 40 mg
Study: 10192751
Drug: Topical heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical heparin (1000 IU x g(‐1), applied three times daily for a maximum of 7 days)
Study: 10192751
Drug: Topical heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical heparin and Placebo
Study: 7587700
Drug: BCG instillation
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG instillation therapy
Study: 7587700
Drug: TTP instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTP instillation therapy
Study: 7587700
Drug: MMC instillation
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC instillation therapy
Study: 7587700
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no instillation therapy)
Study: 2271367
Drug: Clomipramine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (75 mg for extensive metabolisers, 50 mg for poor metabolisers)
Study: 2271367
Drug: Desipramine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (200 mg for extensive metabolisers, 50 mg for poor metabolisers)
Study: 231736
Drug: metoclopramide syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide syrup
Study: 231736
Drug: prochlorperazine tablets
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prochlorperazine tablets
Study: 31564689
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy using purified cedar allergen
Study: 29692285
Drug: Metacognitive Reflection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacognitive Reflection and Insight Therapy (MERIT), 40 sessions
Study: 23312052
Drug: IPE 4
Normalized name: miconazole/cleanser 17 on wipe 4 % (200 mg)-2 % (9 gram) VAGINAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPE 4 g/day
Study: 23312052
Drug: IPE 2
Normalized name: miconazole/cleanser 17 on wipe 2 % (100 mg)-2 % VAGINAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPE 2 g/day
Study: 23040523
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist acyline
Study: 19190344
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg supplemental vitamin E (alpha‐tocopherol) per day
Study: 16723156
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of intravenous methylprednisolone
Study: 11115208
Drug: Guideline-concordant antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-concordant antidepressant medication or specialty counseling
Study: 1528609
Drug: Low-dose antigen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose antigen injection
Study: 3877291
Drug: Pethidine 50‐75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine 50‐75 mg intramuscularly and atropine 0.6 mg intramuscularly
Study: 31862740
Drug: Fascia iliaca
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascia iliaca compartment block (FICB) administered by trained paramedics
Study: 29246363
Drug: Brain natriuretic
Normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain natriuretic peptide (≥100 pg/mL)
Study: 29246363
Drug: TNF‐α (≥5.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF‐α (≥5.6 pg/mL)
Study: 29246363
Drug: Troponin (≥0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troponin (≥0.01 ng/mL)
Study: 21149931
Drug: NEUMUNE (5‐androstenediol
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEUMUNE (5‐androstenediol injectable suspension) administered intramuscularly at doses of 50, 100, 200 or 400 mg, either as a single injection or once daily for five consecutive days
Study: 18057405
Drug: Caffeine supplement
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine supplement
Study: 16598180
Drug: Self-etching adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-etching adhesive system (Adper Prompt L Pop) applied without prior acid etching
Study: 12112791
Drug: Salmeterol xinafoate
Normalized name: Salmeterol Xinafoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol xinafoate inhalation before sleep
Study: 11951580
Drug: Hymecromone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hymecromone (300 mg tablets at a dosage of 1,200 mg/day, 2 tablets midday and evening)
Study: 7908864
Drug: BRL 35135
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRL 35135 (8 mg)
Study: 2675854
Drug: Salbutamol (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (8 mg)
Study: 7908864
Drug: Nadolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (20 mg)
Study: 1865159
Drug: Intensified conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified conventional treatment (ICT)
Study: 2671247
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment (RT)
Study: 30575798
Drug: ω‐3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 supplementation (triglyceride dietary supplements or prescription ethyl esters)
Study: 30575798
Drug: Endotoxin challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotoxin challenge (low dose intravenous lipopolysaccharide)
Study: 27939192
Drug: Ultrasound-guided serratus
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided serratus anterior plane block (SAPB) with 30 mL of 0.25% levobupivacaine followed by 5 mL/hour of 0.125% levobupivacaine
Study: 27939192
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural analgesia (TEA) with a lower dose regimen activated before extubation
Study: 23545279
Drug: nab-paclitaxel (nab-P)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel (nab-P) 100 mg/m² weekly + carboplatin (C)
Study: 23545279
Drug: solvent-based paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: solvent-based paclitaxel (sb-P) 200 mg/m² every 3 weeks + carboplatin (C)
Study: 10878692
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR 180 mg/trandolapril 2 mg (VT)
Study: 10878692
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg/hydrochlorothiazide 25 mg (CH)
Study: 22960888
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow mononuclear cell therapy
Study: 17001575
Drug: Simeticone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeticone (300 mg) administered 20 min before capsule endoscopy
Study: 10494365
Drug: Dimenhydrinate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimenhydrinate (1 mg x kg‐1)
Study: 11413698
Drug: Droperidol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (15 micrograms x kg‐1) + Dimenhydrinate (1 mg x kg‐1)
Study: 8215477
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of mitomycin C combined with PJ-203 (600 +/- 300 mg)
Study: 8215477
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of mitomycin C alone (control)
Study: 8215477
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of mitomycin C combined with PJ-203
Study: 3441275
Drug: Scopolamine (0.25-0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.25-0.75 mg i.m.)
Study: 3441275
Drug: Scopolamine (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.50 and 0.75 mg i.m.)
Study: 3441275
Drug: Scopolamine (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.75 mg i.m.)
Study: 3441275
Drug: Scopolamine (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.50 mg i.m.)
Study: 20479485
Drug: Glucose-only beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-only beverage (G)
Study: 18533979
Drug: Immediately loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately loaded implants with a coil spring
Study: 18533979
Drug: Nonloaded implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonloaded implants with an annealed coil spring
Study: 12756602
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) administered to 91 patients in the AG group
Study: 1845926
Drug: Propranolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (beta 1/beta 2-antagonist)
Study: 1845926
Drug: Atenolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (beta 1-antagonist)
Study: 31883703
Drug: Gantenerumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gantenerumab (300 mg SC injection) at 5 seconds
Study: 31883703
Drug: Gantenerumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gantenerumab (300 mg SC injection) at 15 seconds
Study: 31883703
Drug: Placebo (SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (SC injection into abdomen)
Study: 31883703
Drug: Placebo (SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (SC injection into thigh)
Study: 31883703
Drug: Gantenerumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gantenerumab (300 mg SC injection)
Study: 23535882
Drug: SpineCor brace
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SpineCor brace treatment
Study: 19767804
Drug: Isotonic sports
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sports drink containing caffeine (6.4 g carbohydrate and 16 mg caffeine per 100 mL)
Study: 9092955
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 400 mg/day
Study: 9092955
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 600 mg/day
Study: 9092955
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 800 mg/day
Study: 8244132
Drug: Heater probe
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heater probe treatment
Study: 3533562
Drug: bufuralol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: bufuralol (60 mg)
Study: 3533562
Drug: propranolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol (160 mg)
Study: 3533562
Drug: bufuralol (30-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: bufuralol (30-60 mg bd)
Study: 3533562
Drug: propranolol (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol (40-80 mg bd)
Study: 31255349
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (HP) - 35% protein (1.34 g/kg/day)
Study: 31255349
Drug: Standard-protein diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-protein diet (SP) - 18% protein (0.75 g/kg/day)
Study: 20185740
Drug: Ezetimibe plus
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe plus weight loss (10 mg/day)
Study: 18600034
Drug: Hydrocortisone (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (daily dose = 40 mg)
Study: 10379635
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (0.1 U x kg‐body‐weight(‐1))
Study: 10379635
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (0.1 U x kg‐body‐weight(‐1))
Study: 8682965
Drug: Clindamycin 1%
Normalized name: BENZOYL PRX 5%/CLINDAMYCIN 1% GEL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 1% topical solution
Study: 6751705
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg xipamide daily for 7 days
Study: 6751705
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg frusemide daily for 7 days
Study: 29314376
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral D-amphetamine
Study: 26031764
Drug: Finasteride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (1 mg/day)
Study: 26031764
Drug: Combined medication
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined medication (Finasteride + 5% Minoxidil)
Study: 23057323
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose beta-conglycinin (4.6g in 8 test tablets daily)
Study: 23057323
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose beta-conglycinin (2.3g in 4 test tablets daily)
Study: 23057323
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 tablets containing no beta-conglycinin)
Study: 21527026
Drug: Omalizumab (anti-IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (anti-IgE therapy)
Study: 15774788
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m2 weekly for 9 cycles)
Study: 15774788
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m2 every 2 weeks for 4 cycles)
Study: 12361192
Drug: ACEI +
Normalized name: Veneno de Abeja Aceite de Vibora
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI + NAC (600 mg t.i.d.)
Study: 8303575
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily fractionation schedules of 1.2 Gy/fraction, 1.4 Gy/fraction, and 1.6 Gy/fraction with an interfraction interval of four to six hours.
Study: 30409443
Drug: MV-CHIK (5×10^4
Approvals — FDA: no, EMA: no, PMDA: no
Description: MV-CHIK (5×10^4 or 5×10^5 50% tissue culture infectious dose)
Study: 23646470
Drug: Yiqi Qushi
Normalized name: INTERLEUKIN 15 RECEPTOR .ALPHA. CHAIN (HUMAN SUSHI DOMAIN-CONTAINING FRAGMENT) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN FC FRAGMENT), DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Qushi Recipe (YQR), one dose daily for eight weeks
Study: 23646470
Drug: Pyridostigmine 60
Normalized name: pyRIDostigmine 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine 60 mg, three times a day for eight weeks
Study: 19736635
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of warfarin therapy
Study: 19736635
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of warfarin therapy
Study: 16354711
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (15-30 mg elemental zinc daily for 14 days)
Study: 10709819
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 10 g over 20 minutes before sternotomy
Study: 1928856
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of fentanyl 3 micrograms.kg‐1.h‐1 (Group I)
Study: 1928856
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of fentanyl 1 microgram.kg‐1.h‐1 and enflurane 1.2 +/‐ 0.3 vol % (Group II)
Study: 20455619
Drug: Quitline telephone
Normalized name: quinoline yellow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quitline telephone counseling for smoking cessation; details on dosage and duration not available.
Study: 12440177
Drug: forced diuresis
Normalized name: benzalkonium chloride Topical Solution [Clean Force]
Approvals — FDA: no, EMA: no, PMDA: no
Description: forced diuresis with i.v. crystalloid, furosemide, mannitol (if pulmonary capillary wedge pressure was < 20 mmHg), and low dose dopamine
Study: 12440177
Drug: intravenous crystalloid
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous crystalloid and matching placebos
Study: 7573992
Drug: Computer-controlled infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Computer-controlled infusion of alfentanil (CCiA)
Study: 7573992
Drug: Patient-controlled administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled administration of morphine (PCAM)
Study: 7128131
Drug: Standardized dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized dose of ethinyl estradiol
Study: 23837673
Drug: Allocation to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allocation to treatment group
Study: 21034687
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy + risperidone
Study: 21034687
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy + placebo
Study: 21034687
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy + placebo
Study: 21034687
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (cognitive therapy + risperidone, cognitive therapy + placebo, supportive therapy + placebo)
Study: 19158975
Drug: Paroxetine CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine CR (12.5-50 mg/day)
Study: 14517708
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg daily for 6 days)
Study: 11063909
Drug: Alpha-tocotrienyl acetate
Normalized name: alpha-Tocopherol acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpha-tocotrienyl acetate (250 mg/d)
Study: 11063909
Drug: Gamma-tocotrienyl acetate
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-tocotrienyl acetate (250 mg/d)
Study: 11063909
Drug: Delta-tocotrienyl acetate
Normalized name: delta 9-tetrahydrocannabinol acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta-tocotrienyl acetate (250 mg/d)
Study: 8817801
Drug: treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment A
Study: 8817801
Drug: treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment B
Study: 1433686
Drug: High-dose epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose epinephrine (HDE, 15 mg)
Study: 1433686
Drug: Standard-dose epinephrine
Normalized name: epinephrine Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose epinephrine (SDE, 1 mg)
Study: 1433686
Drug: High-dose norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose norepinephrine (NE, 11 mg)
Study: 31698361
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin plus aspirin
Study: 28832630
Drug: Budesonide/formoterol 160/4.5ug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 160/4.5ug twice daily (group II)
Study: 28832630
Drug: Budesonide/formoterol 320/9ug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 320/9ug twice daily (group III)
Study: 28832630
Drug: Budesonide/formoterol 160/4.5ug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 160/4.5ug twice daily with tiotropium 18ug once daily (group IV)
Study: 28832630
Drug: Tiotropium 18ug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18ug once daily (group I)
Study: 25879343
Drug: Capecitabine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1,000 mg/m² daily) and oxaliplatin (85 mg/m² IV)
Study: 25879343
Drug: 5-FU (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU (350 mg/m²) and leucovorin (20 mg/m²)
Study: 23290547
Drug: Intracoronary enalaprilat
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary enalaprilat (50 μg)
Study: 21088675
Drug: Lipid-heparin infusion
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-heparin infusion
Study: 17868864
Drug: Current treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatment modalities for myeloproliferative HES
Study: 17868864
Drug: Current treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatment modalities for idiopathic HES
Study: 17868864
Drug: Current treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatment modalities for lymphocytic‐variant HES